Stem cell factor-activated bone marrow ameliorates amyotrophic lateral sclerosis by promoting protective microglial...

Area of Science:

• Neuroscience
• Immunology
• Regenerative Medicine

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motor neuron loss.
• Current experimental treatments for ALS, including stem cell therapies, have yielded modest therapeutic benefits in animal models.
• A new therapeutic strategy involving bone marrow transplantation (BMT) with activated bone marrow (BM) cells is explored.

Purpose of the Study:

• To investigate the efficacy of bone marrow transplantation (BMT) using stem cell factor (SCF)- or FMS-like tyrosine kinase 3 (flt3)-activated bone marrow (BM) cells in treating the hSOD1(G93A) transgenic mouse model of ALS.
• To determine if SCF or flt3 activation of BM cells can enhance neuroprotection and improve outcomes in ALS.

Main Methods:

• Utilized hSOD1(G93A) transgenic mice, a model for amyotrophic lateral sclerosis (ALS).
• Administered bone marrow transplantation (BMT) with either stem cell factor (SCF)-activated, FMS-like tyrosine kinase 3 (flt3)-activated, or non-activated bone marrow (BM) cells.
• Assessed motor function, survival rates, and spinal cord infiltration of BM-derived cells, including microglia marker Iba1 and glutamate transporter-1 (GLT-1) expression.

Main Results:

• Stem cell factor (SCF) activated bone marrow (BM) cells significantly improved motor function and survival in hSOD1(G93A) mice compared to BMT alone.
• Flt3 activation did not show significant therapeutic benefits.
• SCF activation led to increased migration of BM-derived microglia expressing GLT-1 into the spinal cord, suppressed inflammatory cytokines (TNF-α, IL-1β), and increased neurotrophic factors (IGF-1).

Conclusions:

• Stem cell factor (SCF) activation reprograms bone marrow (BM) cells, enhancing their neuroprotective properties for ALS treatment.
• SCF-activated BM cells represent a promising new therapeutic strategy for amyotrophic lateral sclerosis (ALS).
• The observed neuroprotective effects are attributed to altered immune cell characteristics and modulation of the spinal cord microenvironment.